Literature DB >> 2304047

Domiciliary nebulized pentamidine for secondary prophylaxis against Pneumocystis carinii pneumonia.

S T Green1, D Nathwani, P R Christie, D J Goldberg, D H Kennedy, W C Love.   

Abstract

The viability of a programme for delivering aerosolized pentamidine within the patient's home setting for the secondary prophylaxis of Pneumocystis carinii pneumonia (PCP) has been explored with seven homosexual AIDS patients, the major objectives being the assessment of the safety and acceptability of the treatment and the discovery of the most suitable care setting (home, ward, outpatient clinic) for the administration of therapy. It is concluded that a domiciliary prophylaxis programme is a viable alternative.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2304047      PMCID: PMC1292457          DOI: 10.1177/014107689008300109

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  4 in total

1.  Differences in relative efficiency of nebulisers for pentamidine administration.

Authors:  M J O'Doherty; S Thomas; C Page; D Barlow; C Bradbeer; T O Nunan; N T Bateman
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

2.  Aerosolised pentamidine.

Authors:  A K Simonds; S P Newman; M A Johnson; N Talaee; C A Lee; S W Clarke
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

3.  Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; E N Brunette; E T Lin; P C Hopewell
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

4.  Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. A pilot study.

Authors:  J E Conte; H Hollander; J A Golden
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.